Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UUKOT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
US20250025567A1 ExL7A1
|
|||||
| Synonyms |
US20250025567A1 ExL7A1
Click to Show/Hide
|
|||||
| Organization |
ASTELLAS PHARMA INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.28
|
|||||
| Structure |
|
|||||
| Antibody Name |
anti-hCLDN6 antibody Ab1
|
Antibody Info | ||||
| Antigen Name |
Claudin-6 (CLDN6)
|
Antigen Info | ||||
| Payload Name |
US20250025567A1, ExlL7A1, Payload
|
Payload Info | ||||
| Therapeutic Target |
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
|
Target Info | ||||
| Linker Name |
3-Maleimidopropionic acid linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
N-[ (4-{[2-amino-4- (pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-3-methoxyphenyl)methyl|-N-cyclopropyl-3- (2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamide (trifluoroacetic acid)salt
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | Positive CLDN6 expression (CLDN6+++/++) | ||
| Method Description |
ExL7A1 was tested in SCID mice that subcutaneously transplanted NUGC33, 3 mg/kg was administeredthrough the tail vein of the tumor-bearing mice.
|
||||
| In Vivo Model | NUGC-3 cells SCID mice model | ||||